BAY 11-7082

Catalog No.S2913 Synonyms: BAY 11-7821

BAY 11-7082 Chemical Structure

Molecular Weight(MW): 207.25

BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.

Size Price Stock Quantity  
In DMSO USD 120 In stock
USD 90 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • The inhibition of IκBα phosphorylation by BAY11-7082 (10 µM) was confirmed using western blotting, and GAPDH was used as an internal reference.

    Cancer Lett, 2016, 378(2):131-41. BAY 11-7082 purchased from Selleck.

    Immunofluorescence images of Ishikawa cells showing the increase in the nuclear colocalization of ERa (red) and p65 (green) after E2 incubation. Nuclear colocalization is yellow. Treatment with ICI 182,780, PDTC or Bay inhibited the nuclear localization of both ERa and p65. Blue, DAPI-stained nuclei. All pictures were obtained the same day using the same microscope settings. Original magnification 3200, bar =50 um. Arrows, cytoplasmic ERa and p65 staining. ICI, ICI 182,780; Bay, Bay 11-7082.

    Int J Cancer 2014 135(2), 282-94. BAY 11-7082 purchased from Selleck.

  • Shown are Western blot analysis of Wnt5a expression in HDPCs treated with TNF-a (n=3–4). The gene expression level was normalized to GAPDH (n = 3–6). HDPCs were preincubated with pyrrolidinedithiocarbamic acid (PDTC, an NF-κB inhibitor), BAY11-7082 (an NF-κB inhibitor), SP600125 (a JNK inhibitor), SB203580 (a p38 inhibitor), or U0126 (an ERK inhibitor) before treatment with TNF-a.

    J Biol Chem 2014 289(30), 21028-21039. BAY 11-7082 purchased from Selleck.

    The effect of vaspin on TNF α -induced THP-1 cell adhesion to HAECS measured staining with VibrantDiO® Cell-Labeling Solution. The level of THP-1 cell adhesion to HAECs was measured at 4 hr after treatment with 25 -100 ng/mL vaspin in the presence or absence of 10 ng/mL TNF α . BAY11-7082 (10 uM, S2913, Selleckchem, USA), an inhibitor of NF- κ B, was used as a positive control.

    Cardiovasc Diabetol 2014 13, 41. BAY 11-7082 purchased from Selleck.

  • Reverse transcription-quantitative polymerase chain reaction assays revealed the effect of atorvastatin on visfatin-induced inflammation. Human coronary artery endothelial cells were incubated in the absence or presence of 50 ng/ml visfatin, with or without 50 nM FK866, 50 µM BAY11-0782 or 10 µM atorvastatin, for 24 h. (A) Atorvastatin downregulated visfatin-induced IL-6 gene expression (P-values from left to right vs. control: 0.0081, 0.0045, 0.0233 and 0.0057). (B) Atorvastatin decreased visfatin-induced IL-8 gene expression (P-values from left to right vs. control: 0.0096, 0.0037, 0.0043 and 0.0031). (C) Atorvastatin downregulated visfatin-induced IL-6 release (P-values from left to right vs. control: 0.0078, 0.0022, 0.0783 and 0.0382). (D) Atorvastatin inhibited visfatin-induced IL-8 release (P-values from left to right vs. control: 0.0094, 0.0032, 0.0039 and 0.0035). Significant differences were determined using Student's t-test; *P<0.05, **P<0.01 vs. visfatin control. IL-6, interleukin-6; IL-8, interleukin-8.

    Oncol Lett, 2016, 12(2):1438-1444. BAY 11-7082 purchased from Selleck.

Purity & Quality Control

Choose Selective IκB/IKK Inhibitors

Biological Activity

Description BAY 11-7082 is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. Also inhibiting components of the ubiquitin system.
Targets
E2-conjugating enzymes [6]
(Cell-free assay)
IκBα phosphorylation [1]
(Tumor cells)
10 μM
In vitro

BAY 11-7082 completely and specifically abrogates NF-κB DNA binding, downregulating the NF-κB-inducible cytokine IL-6 and inducing apoptosis. [1] BAY 11-7082 (< 8 μM) is able to effectively inhibit both basal and TNFα stimulated NFκB luciferase activity in a dose dependent manner. BAY 11-7082 (8 μM) strongly inhibits the rate of proliferation in NCI-H1703 cells. [2] Bay 11-7082 (5 μM) rapidly and efficiently reduces the DNA binding of NF-kappaB in HTLV-I-infected T-cell lines and down-regulates the expression of the antiapoptotic gene, Bcl-x(L), whereas it has little effect on the DNA binding of another transcription factor, AP-1. Bay 11-7082-induced apoptosis of primary ATL cells is more prominent than that of normal peripheral blood mononuclear cells, and apoptosis of these cells is also associated with down-regulation of NF-kappaB activity. Bay 11-7082 (5 μM) selectively induces apoptosis of HTLV-I–infected T-cell lines associated with down-regulation of the expression of cyclin D1, cyclin D2, and Bcl-xL. [3] BAY 11-7082 (100 μM) prevents the nuclear translocation of p65 elicited by NMDA and the NMDA-induced increase of NF-κB binding in mouse hippocampal slices. BAY 11-7082 prevents NMDA toxicity occurring in CA1 region of hippocampal slices with 40% neuroprotection at 20 μM and 70% neuroprotection at 100 μM. [4] BAY 11-7082 at all concentrations tested significantly inhibits NF-κB p65 DNA-binding activity in adipose tissue, whereas in skeletal muscle, BAY 11-7082 at 50 μM and 100 μM significantly inhibits NF-κB p65 DNA-binding activity. BAY 11-7082 (100 μM) reduces IKK-β protein in human adipose tissue and skeletal muscle. BAY 11-7082 (100 μM) significantly decreases the release of TNF-α from adipose tissue, whereas the release of IL-6 and IL-8 is significantly inhibited at all concentrations of BAY 11-7082 tested. BAY 11-7082 (50 μM) significantly decreases the release of TNF-α, IL-6, and IL-8 in skeletal muscle. [5] BAY 11-7082 is also found to inactivate the E2-conjugating enzymes Ubc (ubiquitin conjugating) 13 and UbcH7 and the E3 ligase LUBAC (linear ubiquitin assembly complex), and thus induces B-cell lymphoma and leukaemic T-cell death. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HeLa NGL0UmZHfW6ldHnvckBCe3OjeR?= MnjNNVDDqM7:TR?= MnrzNU42KGh? MkDRZYJwdGm|aHXzJGJRSSCrbnT1Z4VlKHWyIILl[5Vt[XSrb36gc4YhTk5iYX7kJG1OWC17wrC= NHjS[2YzPTd7N{SzOy=>
SiHa  MVXGeY5kfGmxbjDBd5NigQ>? M4nKSFExyqEQvF2= NYDq[opVOS53IHi= M{HpSIFjd2yrc3jld{BDWEFiaX7keYNm\CC3cDDy[Yd2dGG2aX;uJI9nKE[QIHHu[EBOVVBvOdMg NUK2VZIxOjV5OUe0N|c>
ARPE-19 NYC2UnRwTnWwY4Tpc44hSXO|YYm= Mn\jNUDPxE1? M1vJS|AvPSCq Mon2d5VxeHKnc4Pld{BVTy2rbnT1Z4VlyqCLTD24xsBxem:vb4TldkBi[3SrdnH0bY9v M4DFRVI2PTl|MEK5
HCT116 M4DuSmZ2dmO2aX;uJGF{e2G7 NHfMSZo2KM7:TR?= M1TDN|IhcA>? NUDQV5FuTE2VTx?= NWjwToNy[XS2ZX71ZZRmeyC|aXz5cYFzcW5vaX7keYNm\CCmb4fudoVofWyjdHnvckBw\iCleXPsbY4hTDF? NYXDc|h[OjV2N{m3NlM>
HMECs NVW5NHZkTnWwY4Tpc44hSXO|YYm= MlrnOeKh|ryP NVnEWZBNOiCq Mlq4ZYJwdGm|aHXzJHRPTi4QsT3pcoR2[2WmIG\DRW0uOSCneIDy[ZN{cW:wwrC= MmnzNlUyQTNzMU[=
A549  NG[wPY1HfW6ldHnvckBCe3OjeR?= MlWwNVDjiIoEtV2= M{XsVVEzKGh? MnS1d5VxeHKnc4Pld{BFfmxvMzDpcoR2[2WmIHHjeIl3[XSrb36gc4YheDZ3 MVKyOVE2PjhyMB?=
RAW 264.7 MU\GeY5kfGmxbjDBd5NigQ>? M3Tyc|XDqM7:TR?= NVvlZZpGOSCq M4KxUolvcGmkaYTzJHRPTi4QsTDhcoQhUUxvMUKgdFQxKHC{b3T1Z5Rqd25? NWL3SmlKOjVyMUm1Olc>
macrophages NX3PTFFjTnWwY4Tpc44hSXO|YYm= NFfYTXk2KML3TR?= MmKyN{Bp MY\wZZJ1cWGubImgZoxw[2u|IGnQSnMucW6mdXPl[EBmgHC{ZYPzbY9vKG:oIHnOU3Mh[W6mIFPPXE0zyqB? MXOyOFk3Pzh7OB?=
HUVECs NFzWNoNHfW6ldHnvckBCe3OjeR?= M2XkeVMuOzBizszN NWPMOpZoOSCq NE\G[HJz\WS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJI1qWi1zNE\hJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NV;NcFFHOjR6NkO5OlU>
HeLa  M2j6UGZ2dmO2aX;uJGF{e2G7 MoSwOeKh|ryP M2XxR|I1KGh? NFjPU4VFVVOR MXry[YR2[2W|IITo[UBi[3Srdnn0fUBw\iCWTl[t{tEheHKxbX;0[ZLDqA>? MljrNlQ3PTd5OEO=
A549 NFuwcmdHfW6ldHnvckBCe3OjeR?= NVPRNpRrOTBizszN MYGx5qCKcA>? MYXpcohq[mm2czD0bIUhcW6lcnXhd4Uhd2ZicHjvd5Bpdy2LzsrC{tEhcW5iUFGxNFMucW6oZXP0[YQh[3WudIXy[ZPDqA>? NYjj[Y15OjR4MUK0PFg>
HUVEC MVfGeY5kfGmxbjDBd5NigQ>? NV3veVBzOjBiwsXN NF\lOosxNjViaB?= NW\5eW8xTE2VTx?= NWfzU|I1eHKndnXueJMhfGinIHnu[JVkfGmxbjDv[kBGSU1iZYjwdoV{e2mxbh?= M3qyR|I1PTVzMkC5
A549RT-eto MmTNRZBweHSxc3nzJGF{e2G7 MkHRNVDDqM7:TR?= M17ONFI1KGh? Ml3KSG1UVw>? M1L5WoFk[2WuZYLheIV{KE[HUl:tcYVlcWG2ZXSgZZBweHSxc3nz NX\qcVd5OjR3M{WwPFM>
THP-1  MkDvSpVv[3Srb36gRZN{[Xl? NIH1NXMxNjFxMdMg{txO NG\ONXIxNjViaB?= NUX4e|Q6[WK{b3fheIV{KFSQRj5OtUB{\WO{ZYTpc44h[XNid3XscEBieyC2aHWgbY5kemWjc3XkJJNm[3KndHnvckBw\iCLTD22JIFv\CCLTD2x{tI> MnfENlQ{Pzh3M{[=
SKCXCR2  NHP2SYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFWyfXczKML3TR?= NH7pN2Q1QCCq M1:4fIRm[3KnYYPld{Bk\WyuIIDyc4xq\mW{YYTpc44he2mpbnnmbYNidnSueR?= MX6yOFM4Pjd2Nx?=
SKCXCR2  M{e2OmZ2dmO2aX;uJGF{e2G7 MXKyJOK2VQ>? NIfLW401QCCq NH\NUpRjdG:la4OgeIhmKEO[Q1yxMYlv\HWlZXSgZ4VtdCCrbo\hd4lwdg>? MVSyOFM4Pjd2Nx?=
OVCXCR2 MU\GeY5kfGmxbjDBd5NigQ>? M3\yR|IhyrWP NUPSbpNJPDhiaB?= NXTWdmtm[myxY3vzJJRp\SCFWFPMNU1qdmS3Y3XkJINmdGxiaX72ZZNqd25? M{D4OVI1Ozd4N{S3
DSCs  MXnGeY5kfGmxbjDBd5NigQ>? MoTiNk42KM7:TR?= NVvFTVAxOC53IHi= MkXOdoV3\XK|ZYOgeIhmKGWwaHHuZ4Vu\W62IH;mJGNEVDJxQ1PSNkBmgHC{ZYPzbY9vKG:oIFTTR5MhcW6mdXPl[EBjgSCLTD2zNy=> NF\KOVQzPDN2NEK0NC=>
WPs MUPGeY5kfGmxbjDBd5NigQ>? NF;rOYwzPSEQvF2= MYK1JI1qdg>? NVP1SldCe3WycILld5NmeyCDVGCgZY5lKH[ZRjDz[YNz\XSrb36= NYfDV2RyOjR|M{GyNFc>
A549RT-eto MUDBdI9xfG:|aYOgRZN{[Xl? MWixNOKh|ryP NV75[YRNOjRiaB?= M4nI[oFk[2WuZYLheIV{KEZzNDDlfJRz[WO2LX3l[IlifGWmIHHwc5B1d3OrczDjc41jcW6nZDD0doVifG2nboSge4l1cCCIMUS= MlK1NlQzOjB5MkW=
A549RT-eto MXfGeY5kfGmxbjDBd5NigQ>? Ml\XNVDDqM7:TR?= MX:yOEBp M1Ww[oRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdHNib3[gUmYu|rqEIHHu[EBRNWeywrC= NFHiO2gzPDJ{MEeyOS=>
FaDu M3\FZWZ2dmO2aX;uJGF{e2G7 NFvpZZAzKGh? M1:xSIlvcGmkaYTzJJA3PSCneIDy[ZN{cW:wIHHu[EBjdG:la4OgWG5H|rFvaX7keYNm\CCWV1nTWEBmgHC{ZYPzbY9v M2jWe|I1OjJyNkKy
IVD  M2DsSmZ2dmO2aX;uJGF{e2G7 NYPRN5NbOTEEoN88US=> M2rkd|Mh\A>? M4W5VZJmfmW{c3XzJHRPTi4QsfMAl41m\GmjdHXkJJN2eHC{ZYPzbY9vKG:oIITo[UBlcXOlIH3heJJqgCCvYXPyc41wdGWldXzld{Bi\2e{ZXPhckBidmRiY3;scIFo\W5iSVm= NHHUUHIzPDF5NkiwPC=>
IVD  M2fPc2Z2dmO2aX;uJGF{e2G7 M2SzSVExyqEQvF2= MlvZN{Bl MUThZpJw\2G2ZYOgWG5HNc7z4pETbY5lfWOnZDD1dE1z\We3bHH0bY9vKG:oIFHERW1VWy12IHHu[EBCTEGPVGOtOeKh M2qwVFI1OTd4OEC4
iNKT NWCxOYNqTnWwY4Tpc44hSXO|YYm= NV33eGZbOTBxMUCwJO69VQ>? MkDsNE42KGh? MmTEbY5pcWKrdIOgeIhmKGmwZIXjeIlwdiCxZjDBNmFTKG2UTlGgZY5lKG:2aHXyJIZi[3Sxch?= MlPWNlQyOjR2NUO=
PC-3 MmjxSpVv[3Srb36gRZN{[Xl? NX\SdIZqOi53L{WvNVAh|ryP MYqwMlUhcA>? NVH5[VBk[myxY3vzJGlITi2LST3pcoR2[2WmIGPUV{BuWk6DIHX4dJJme3Orb39CpC=> NXP4Smc{OjRyNUW1NlA>
THP-1  NEnJdHJHfW6ldHnvckBCe3OjeR?= M{DBOFExyqEQvF2= M2HCV|HDqGh? M13VVYFjd2yrc3jld{B1cGViZX\m[YN1KG:oIILIV3AzPyCxbjDTVk1CKG2UTlG= M2rzXVI{QTN7M{m4
A549 NWrCfmdSTnWwY4Tpc44hSXO|YYm= NWXTbXBYOcLizszN NVvLWIFSPDhiaB?= NWi2bXNG\W6qYX7j[ZMhfGinIIXwMZJm\3WuYYTpc44hd2ZiSd86RkBidmRic4Xid4VyfWWwdDDk[YNz\WG|ZTDpckBD[XhiZYjwdoV{e2mxbjDpcoR2[2WmIHL5JINwdWKrbnXkJJN1cW23bHH0bY9v NUfNWplpOjN7MECwPFA>
A549 NVvp[|ExSXCxcITvd4l{KEG|c3H5 MnfSNeKh|ryP NFOyNmw1QCCq MX;y[YR2[2W|IITo[UBk\WyuIHTlZZRpKGmwZIXj[YQh[nliY3;tZolv\WRic4TpcZVt[XSrb36= MlfXNlM6ODByOEC=
NCI-N87 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fMclExNzJyL{OwJO69VQ>? M4f0XlYwOjRiaB?= NF7ycI9{fXCycnXzd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? MV6yN|g1PjV2NR?=
AGS MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVuxNE8zOC9|MDFOwG0> MnzOOk8zPCCq MWLzeZBxemW|c3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MlvXNlM5PDZ3NEW=
MGC80-3 Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnP6NVAwOjBxM{Cg{txO MX22M|I1KGh? NUXadXZpe3WycILld5NmeyClZXzsJJZq[WKrbHn0fUB{cWewaX\pZ4FvfGy7 M{nyflI{QDR4NUS1
HGC-27  NWLOSHFsTnWwY4Tpc44hSXO|YYm= M3TnUlcvPS9zNT:zNEDPxE1? MnPQOkBp MorBbY5lfWOnczD0bIUh\GWyaH;zdIhwenmuYYTpc44h[W6mIIXwMZJm\3WuYYTpc44hd2ZiSd86Ru6y NUKzSHo{OjN6NE[1OFU>
MGC80-3 M130fGZ2dmO2aX;uJGF{e2G7 NIDwU204NjVxMUWvN|Ah|ryP MYC2JIg> NUW0RXFCcW6mdXPld{B1cGViZHXwbI9{eGixconsZZRqd25iYX7kJJVxNXKnZ4XsZZRqd25ib3[gTe67Ss7z NV\6[IdvOjN6NE[1OFU>
HGC-27  MVvBdI9xfG:|aYOgRZN{[Xl? MlrRO{42NzF3L{OwJO69VQ>? M3;4VFYhcA>? NFHlfoxqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUTnT3pbOjN6NE[1OFU>
HBE  NYP2OHV{TnWwY4Tpc44hSXO|YYm= M3jwbFEx|ryP MkfZN4g> MV3hZo9tcXOqZYOgeIhmKGmwY4LlZZNmeyCxZjDJUE03KGW6cILld5Nqd25iaX7keYNm\CCkeTDDV2U> M3fmNFI{QDJ2MEi5
HepG2 MXfGeY5kfGmxbjDBd5NigQ>? NXjROJpkOC5|L{GvN{DPxE1? NIjsOpA1QCCq M1T5N5Jm\HWlZYOgTWw3NWmwZIXj[YQhWE:QMTDlfJBz\XO|aX;u MUGyN|c6OTh|Mx?=
THP-1 NIGzVVJHfW6ldHnvckBCe3OjeR?= MXy1JOK2VQ>? NUfzS2RPOSCq NWOxfWR7TE2VTx?= NGn6PGxqdmirYnn0d{BOXEJvaX7keYNm\CCQRt86RkBi[3SrdnH0bY9v NU\RU3lFOjN4M{SyNVg>
THP-1  M{G3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7ROUDDvU1? M{fOUFQwQCCm MWDEUXNQ M4LnVZJm\HWlZYOgeIhmKH[rYXLpcIl1gSCxZjDpcpRz[WOnbHz1cIFzyqCPVFK= NF7mOZkzOzZ|NEKxPC=>
MDM MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIflUmM2KML3TR?= MlTHOE85KGR? M3;Bd2ROW09? MV3y[YR2[2W|IITo[UB3cWGkaXzpeJkhd2ZiaX70doFk\WyudXzhduKhVVSE M3LQdlI{PjN2MkG4
AM MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVi1JOK2VQ>? M{fwZlQwQCCm NFv0SZpFVVOR M3TuT5Jm\HWlZYOgeIhmKH[rYXLpcIl1gSCxZjDpcpRz[WOnbHz1cIFzyqCPVFK= MnfMNlM3OzR{MUi=
RAW 264  MojZSpVv[3Srb36gRZN{[Xl? NYe2NFByOC5{LUWgxtVO NEfufIQ{OC94MD:5NEBucW5? NX7yUFV2cW6qaXLpeJMhfGinIIDoc5NxcGG2YYPlJIFkfGm4aYT5JI9nKFCWUEHCxsA> NV;2NGNZOjN3N{izNFI>
HUVEC MXTGeY5kfGmxbjDBd5NigQ>? MnfzNVDDqM7:TR?= NXn2W2tbOC53IHi= NVHZ[XZ7TE2VTx?= MnrWZ492dnSncnHjeIV{KHSqZTDsc5N{KG:oIGTp[VIhdVKQQR?= M4PXUFI{PTZ|NkOy
HT29 NHO4UHlHfW6ldHnvckBCe3OjeR?= M4nJZVExNzNyL{GwNEDPxE1? MYSxJIg> NYTiTmszcW6qaXLpeIV{KGKxdHigWHdGSUtvaX7keYNm\CCyMUCwJJBzd2Onc4Ppcoc> NFu0coczOzV{N{G1OC=>
HT29 M3TE[mZ2dmO2aX;uJGF{e2G7 NELr[msyOC9|MD:xNFAh|ryP Mnf3NUBp Ml7NbY5pcWKrdIOgWG5HNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJIFv\CCmZXfyZYRifGmxbjDv[kBK|rqEzsG= MU[yN|UzPzF3NB?=
MM.1S M1rXc2Fxd3C2b4Ppd{BCe3OjeR?= Mn3TN|AhyrWP NEDYcY8{KGh? MVHpcoR2[2W|IF3NJINmdGxiZHXheIghcW64b3z2[ZMhdmWlcn;zbZM> NYLa[GhROjN3MkexOVQ>
KMS-12-BM M3nDNmFxd3C2b4Ppd{BCe3OjeR?= NFXFUZk{OCEEtV2= MV[zJIg> NYj6[lRJcW6mdXPld{BOVSClZXzsJIRm[XSqIHnueo9tfmW|IH7lZ5Jwe2m| MYSyN|UzPzF3NB?=
BAFs NHHrbmZHfW6ldHnvckBCe3OjeR?= M1rYNVAvPS9zwrFOwG0> MnXNNlQhcA>? NHLzXo9qdmirYnn0d{BVVkcQsT;ESXghcW6mdXPl[EBEYVBzOVGxxsB1emGwc3PybZB1ew>? NF74bWYzOzR6NUS1Oy=>
SP6.5 MXrGeY5kfGmxbjDBd5NigQ>? NGPS[Wc2KM7:TR?= MkPkNkBp MoS2[IVkemWjc3XzxsB1emGwc3zvZ4F1cW:wIH;mJJA3PSCrbjD0bIUhdnWlbHX1d:Kh MVyyN|Q1OzB6Nh?=
VUP M{HtdWZ2dmO2aX;uJGF{e2G7 M33KOlUh|ryP M{fxV|IhcA>? MknB[IVkemWjc3XzxsB1emGwc3zvZ4F1cW:wIH;mJJA3PSCrbjD0bIUhdnWlbHX1d:Kh NYK0elFmOjN2NEOwPFY>
OCM1 MnL6SpVv[3Srb36gRZN{[Xl? MljCOUDPxE1? MmPoNkBp NHrFWnZl\WO{ZXHz[ZPDqHS{YX7zcI9k[XSrb36gc4YheDZ3IHnuJJRp\SCwdXPs[ZV{yqB? NH3pVIEzOzR2M{C4Oi=>
OM431 MU\GeY5kfGmxbjDBd5NigQ>? MXG1JO69VQ>? NV;mdXRtOiCq NVzCOI5O\GWlcnXhd4V{yqC2cnHud4xw[2G2aX;uJI9nKHB4NTDpckB1cGViboXjcIV2e8Li MXyyN|Q1OzB6Nh?=
SP6.5 MoXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjkUXIzNjVvMkCg{txO NVradoFuOjRiaNMg MXTJR|UxRTVizszNMEBmgGirYnn0d{B{fHKxbnegZY51cS2ycn;sbYZmemG2aY\lJIVn\mWldIOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NIXadHgzOzR2M{C4Oi=>
VUP M3PKWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DUPVIvPS1{MDFOwG0> Ml[5NlQhcMLi MkLnTWM2OD13IN88UUwh\XiqaXLpeJMhe3S{b37nJIFvfGlvcILvcIln\XKjdHn2[UBm\m[nY4TzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M165TVI{PDR|MEi2
OCM1 NFfTNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrhT2V4Oi53LUKwJO69VQ>? NGX5O|kzPCCqwrC= MXPJR|UxRTVizszNMEBmgGirYnn0d{B{fHKxbnegZY51cS2ycn;sbYZmemG2aY\lJIVn\mWldIOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NGLZbGkzOzR2M{C4Oi=>
OM431 NFe4UY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLFfmQ{Oi53LUKwJO69VQ>? MmXTNlQhcMLi MVjJR|UxRTVizszNMEBmgGirYnn0d{B{fHKxbnegZY51cS2ycn;sbYZmemG2aY\lJIVn\mWldIOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NEjJNWMzOzR2M{C4Oi=>
SP6.5 M{LYN2Fxd3C2b4Ppd{BCe3OjeR?= MXG1JO69VQ>? M37QPFI1KGkEoB?= MlrobY5lfWOnczDhdI9xfG:|aYRCpC=> NFjYTlYzOzR2M{C4Oi=>
VUP M2DuXWFxd3C2b4Ppd{BCe3OjeR?= MYS1JO69VQ>? NWO1PWJVOjRiaNMg MkTGbY5lfWOnczDhdI9xfG:|aYRCpC=> NIq3TlczOzR2M{C4Oi=>
OCM1 NHmyVFZCeG:ydH;zbZMhSXO|YYm= M1G0PFUh|ryP NEHWbVAzPCCqwrC= NHSybYdqdmS3Y3XzJIFxd3C2b4Ppd:Kh MoTENlM1PDNyOE[=
OM431 MmPaRZBweHSxc3nzJGF{e2G7 MUS1JO69VQ>? NGHHW|QzPCCqwrC= M3TwTIlv\HWlZYOgZZBweHSxc3nzxsA> MYCyN|Q1OzB6Nh?=
SP6.5 NHPkcZJHfW6ldHnvckBCe3OjeR?= MYG1JO69VQ>? M17mcFEzKGh? NXXaS2luemWmdXPld{B1cGVibXnndoF1cW:wwrC= M13CdlI{PDR|MEi2
VUP NILPU2FHfW6ldHnvckBCe3OjeR?= MUm1JO69VQ>? NVrINW9iOTJiaB?= NWX1[5VCemWmdXPld{B1cGVibXnndoF1cW:wwrC= MorwNlM1PDNyOE[=
OCM1 Ml:5SpVv[3Srb36gRZN{[Xl? NWPMbZVFPSEQvF2= NFW2XXMyOiCq MWny[YR2[2W|IITo[UBucWe{YYTpc47DqA>? NGTGU2IzOzR2M{C4Oi=>
OM431 MXvGeY5kfGmxbjDBd5NigQ>? MVK1JO69VQ>? NGnmS3UyOiCq MX;y[YR2[2W|IITo[UBucWe{YYTpc47DqA>? M1S1NVI{PDR|MEi2
HBL-1  M1jUU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUizxsDPxE1? MkLXNlQwPDhxN{KgbC=> NFnDemxFVVOR NEfGfZB{dG:5czDj[YxtKGe{b4f0bEBud2Snc4TsfS=> NFP6boMzOzR2MUezNC=>
RAW 264.7 NWjmN4hiTnWwY4Tpc44hSXO|YYm= NGDzVZIzNTF3IN88US=> MkLhNUBp M2fVeGROW09? NVfDUVY5e3WycILld5NmeyC2aHWgZYN1cX[jdHnvckBw\iCLS1ug[oFucWy7IH3lcYJmenN? NFrlepczOzR2MUezNC=>
IL-1R  MUTGeY5kfGmxbjDBd5NigQ>? NGjxZZEzNTF3IN88US=> NGficG4yKGh? NYK1OFdnTE2VTx?= M3S4fZN2eHC{ZYPz[ZMhfGinIHHjeIl3[XSrb36gc4YhUUuNIH\hcYltgSCvZX3i[ZJ{ NIXOdY8zOzR2MUezNC=>
RAW 264.7 NYnqOodjTnWwY4Tpc44hSXO|YYm= NETONpAyPSEQvF2= MlrjNUBp MXTEUXNQ NHfIXnh{fXCycnXzd4V{KHSqZTDhZ5RqfmG2aX;uJI9nKGGwZDDKUms> M2nwflI{PDRzN{Ow
IL-1R  M1LrfmZ2dmO2aX;uJGF{e2G7 NWD0UVlFOTVizszN NH7yTHUyKGh? MlS2SG1UVw>? NGmyU3R{fXCycnXzd4V{KHSqZTDhZ5RqfmG2aX;uJI9nKGGwZDDKUms> NV7rPJVROjN2NEG3N|A>
U2OS M1vkdWZ2dmO2aX;uJGF{e2G7 M3jMVlE2KM7:TR?= NWLpV3E1OSCq NYD5NI5VTE2VTx?= MYHwdoV3\W62czD0bIUhVFCVLTDvdkBKVC1zLYP0bY12dGG2ZXSg[o9zdWG2aX;uJI9nKEt4Mz3wWYIh[2ijaX7zxsA> MmXONlM1PDF5M{C=
MT‐1  NG[ySIRHfW6ldHnvckBCe3OjeR?= M3\y[ljDqML3bR?= MVWzJIg> M2DpfYRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIIFihLBUXEGWMzDhcoQheOLCkETFRnAy MoPnNlMzPzh2N{m=
MT‐2  M3j6S2Z2dmO2aX;uJGF{e2G7 MlniPOKhyrWv NYXWeZRjOyCq M4LGNIRm[3KnYYPld{B1cGVibHX2[Yx{KG:oIIFihLBUXEGWMzDhcoQheOLCkETFRnAy MVSyN|I4QDR5OR?=
MT‐1  Ml24SpVv[3Srb36gRZN{[Xl? NXvKZpBZQMLiwsXt MlPJN{Bp NHPtO49l\WO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUheDZ3IIP1ZpVvcXRib3[gUmbjiJEQulNCpC=> NYjYTolJOjN{N{i0O|k>
MT‐2  M3HCTWZ2dmO2aX;uJGF{e2G7 NEjDUo05yqEEtX2= NYnpfpppOyCq MWTk[YNz\WG|ZYOgeIhmKGyndnXsd{Bw\iC2aHWgdFY2KHO3YoXubZQhd2ZiTldihLDPwkMEoB?= MmT0NlMzPzh2N{m=
MCF-7  NX7TdnJoTnWwY4Tpc44hSXO|YYm= NXO3WIlbOi53LUG1JO69VQ>? MknONE42KGh? Mny4SG1UVw>? M1fUdYNifXOnczD0bIUh\3KjZIXhcEBtd3O|IH;mJINmdGxiYXTo[ZNqd25? NUHCWGNUOjNyOUOyNlc>
HaCaT  MVPGeY5kfGmxbjDBd5NigQ>? M3LLV|UvOMLizszN NHXTTZAyyqCqwrC= MYXheJRmdnWjdHXzJJRp\SCWQ1;IMYlv\HWlZXSgdJJw\HWldHnvckBw\iCLTD22xsA> MWqyN|A1OTF4OB?=
A549  Ml34SpVv[3Srb36gRZN{[Xl? MnL4NUBp NHvEWFhqdmirYnn0d{BNXEFvaX7keYNm\CCVUD3BJI1TVkFicILv[JVkfGmxbtMgd4lodmmoaXPhcpRtgQ>? NI\WbpgzOzB|MUKxNy=>
OA chondrocytes  NEe4N3RHfW6ldHnvckBCe3OjeR?= MlfCNVAh|ryP MmjTNUBp M{DuUIJtd2OtczD0bIUhSUeHLVLTRU1qdmS3Y3XkJIdmdmVxcILveIVqdiCneIDy[ZN{cW:wIH;mJGdTWDd6IH;yJGNQYC1{IDjwQFAvODVr NWfsRmRvOjJ7OEKyNlg>
RAW264.7 MYjGeY5kfGmxbjDBd5NigQ>? NGDnXnoyPSEQvF2= MVmxOU0yOjBibXnu NVvQ[WtR[myxY3vzJJRp\SCycn;keYN1cW:wIH;mJG5QNCCSR1WyMEBidmRiVF7GMe6y NVftWYlIOjJ5NEW1NlM>
RAW264.7 NVTQTlNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFyzVVI2NTNyIN88US=> MkPRNlQhcA>? MVTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M37uRlIzPzR3NUKz
HBL6 MmPDRZBweHSxc3nzJGF{e2G7 Mn61NE42NzVxMkWg{txO M{TxVVYwOjRiaB?= MnOy[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHHu[EBt\WWjZIOgeI8h[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzyqB? NFjoR24zOjB5NEiyNC=>
HT29  NVLiUW9zTnWwY4Tpc44hSXO|YYm= NYS2RlM2OS1zMDFOwG0> MnTpNVDDqGh? NYm0Om5ycW6lcnXhd4V{KEiRLUGgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u MlvjNlE3OjB7NkS=
Ca9–22 NIHBWIxCeG:ydH;zbZMhSXO|YYm= M1jVOFExyqEQvF5CpC=> NInCb3EyKGh? MnSwZ49ueGyndHXsfUBqdmirYnn0d{BCVEFvUFTUMYlv\HWlZXSgZZBweHSxc3nz NYPCcnQ5OjFzM{i0PFA>
Ca9–22 M370dGZ2dmO2aX;uJGF{e2G7 MlXmNVDDqM7:TdMg NWXqZVd[OSCq NH71cZVkd22ybHX0[Yx6KGGkcn;nZZRmeyC2aHWgRWxCNVCGVD3pcoR2[2WmIFrOT{Bi[3SrdnH0bY9v NVHVTFdvOjFzM{i0PFA>
A-549 MkXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fs[lExyqEQvF5CpC=> NEKySWMzPC92ODDo NWDNRVVLcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MVKyNFg3PjB2Mx?=
AP NUH4VnhGTnWwY4Tpc44hSXO|YYm= M3fDZlUwOTBizszN MXe0PEBp NX;zO3NL\G:5boLl[5Vt[XSnczD0bIUhSkGGIIDyc5RmcW5ibHX2[Ywh[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NXP2NlV2OjB3OU[2OFU>
AQ1 M4jPd2Z2dmO2aX;uJGF{e2G7 MoHVOU8yOCEQvF2= M2nkSFQ5KGh? NUewXFl4\G:5boLl[5Vt[XSnczD0bIUhSkGGIIDyc5RmcW5ibHX2[Ywh[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MkPJNlA2QTZ4NEW=
AP NEHwfJBHfW6ldHnvckBCe3OjeR?= MnPmNlAh|ryP NFjWWFc1NzhiaB?= NWHUdpFN\G:5boLl[5Vt[XSnczD0bIUhSkGGIIDyc5RmcW5ibHX2[Ywh[SC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NWK1fHA{OjB3OU[2OFU>
AQ1 NF\DcndHfW6ldHnvckBCe3OjeR?= MnjONlAh|ryP MXG0M|ghcA>? MlKw[I94dnKnZ4XsZZRmeyC2aHWgRmFFKHC{b4TlbY4hdGW4ZXygZUB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MlPZNlA2QTZ4NEW=
THP-1 MoTQSpVv[3Srb36gRZN{[Xl? MmP0OeKh|ryPwrC= MlTLNE42KGh? NYWxe2Ju[XS2ZX71ZZRmeyC2aHWgUHBUNWmwZIXj[YQheC2LzsrC{tEheHKxdHXpckBjgSB5MjW= NESwW3YzODNyOUexPC=>
K562 MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPWTJdsOi1|MDFOwG0> NYnMPYc{OjRiaB?= MmLSTWM2OD16IN88UUxqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mn33NVk3PDZ6MEe=
Jurket NX3UOm5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TOdFIuOzBizszN M3TBflI1KGh? MlPOTWM2OD15LkGg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M3L1dFE6PjR4OEC3
U937 M1f2SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\0Nk0{OCEQvF2= NX;udm9TOjRiaB?= MX3JR|UxRTFyLkWg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NY\J[4xZOTl4NE[4NFc>
PBMC MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPPSmhZOi1|MDFOwG0> NIqwUFkzPCCq MYXJR|UxRTRyLkKg{txONCCrbnjpZol1eyClZXzsJIdzd3e2aDDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MlHrNVk3PDZ6MEe=
K562 M37UN2Fxd3C2b4Ppd{BCe3OjeR?= MUOyMVIxyqEQvF5CpC=> NHLYRlYzPCCq MlzPbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHHwc5B1d3Orcx?= NXLCUWtGOTl4NE[4NFc>

... Click to View More Cell Line Experimental Data

Protocol

Cell Research:[2]
+ Expand
  • Cell lines: NCI-H1703 cells
  • Concentrations: ~8 μM
  • Incubation Time: 12 hours
  • Method: Cells are transfected with siRNA in 96-well microtiter plates and then cultured for 72 hours in complete NSCLC medium, treated with BAY 11-7082 for 12 hours. Cells are incubated with [3H]thymidine for 3 hours. The cells are collected on filters using an automatic cell harvester and radioactivity on the filters is measured by β-scintillation counting.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 41 mg/mL (197.82 mM)
Ethanol 10 mg/mL (48.25 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+corn oil
For best results, use promptly after mixing.
8mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 207.25
Formula

C10H9NO2S

CAS No. 19542-67-7
Storage powder
in solvent
Synonyms BAY 11-7821

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

IκB/IKK Signaling Pathway Map

IκB/IKK Inhibitors with Unique Features

Related IκB/IKK Products

Tags: buy BAY 11-7082 | BAY 11-7082 supplier | purchase BAY 11-7082 | BAY 11-7082 cost | BAY 11-7082 manufacturer | order BAY 11-7082 | BAY 11-7082 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID